management picture

« Back to Team

Neil Gibson, Ph.D. | Oncology Therapeutics

Neil brings more than 25 years of drug development experience to his role at Janux. Neil has held various senior positions within the biotechnology and pharmaceutical industry, including Senior Vice President at BioAtla, CSO at Regulus Therapeutics, CSO and Oncology Therapeutic Area Head at Pfizer Oncology, and CSO at OSI Pharmaceuticals. While at Pfizer, Neil was also a member of the Pfizer Oncology Business Unit Executive team.

Neil has been involved in the successful discovery, development, and commercialization of four approved oncology drugs including temozolomide, sorafenib, erlotinib, and crizotinib. While at Regulus, Neil was responsible for leading all research and development efforts resulting in 3 distinct oligonucleotides being advanced into clinical development and the establishment of human proof-of-concept with the lead molecule RG-101. Neil has also been involved in the growth of new biotechnology organizations and has conducted significant fundraising. This includes the initial public offering for Regulus Therapeutics, which raised an initial $80.9 million and subsequent follow on financings of about $105 million. He was also involved in the growth of OSI Pharmaceuticals from 100 full-time employees (FTEs) to approximately 750 FTEs and increased market cap of approximately $150 million to more than $4 billion.

Neil has held numerous academic appointments, including Associate Professor at the School of Pharmacy and Comprehensive Cancer Center at University of Southern California, and Fogarty Fellow at the National Cancer Institute at the National Institutes of Health. During his career, Neil has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Neil earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.